GINA FARUZZI: Open Payments
NPI 1881018513 · SANTA BARBARA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$418 in 15 payments from 9 companies in 2025. Trend: 2023 $168 · 2024 $138 · 2025 $418
Food & beverage: $328Education: $90
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 4 | $95 |
| Astellas Pharma US Inc | 1 | $90 |
| Merck Sharp & Dohme LLC | 3 | $61 |
| Janssen Biotech, Inc. | 1 | $44 |
| AstraZeneca Pharmaceuticals LP | 2 | $34 |
| Lilly USA, LLC | 1 | $28 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Adaptive Biotechnologies Corporation | 1 | $23 |
| Novartis Pharmaceuticals Corporation | 1 | $16 |
Products named: BENLYSTA, LYNPARZA, DARZALEX, KEYTRUDA, VERZENIO, Enhertu, JEMPERLI, clonoSEQ.
Industry payments across CA — which companies pay providers there.
